Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Genmab has demonstrated a strong financial position, ending the third quarter of 2025 with approximately $3.4 billion in cash, cash equivalents, and marketable securities, which provides a solid foundation for ongoing operations and R&D investment. The latest reported sales for DARZALEX exceeded prior estimates, with 4Q25 royalties projected to reach $722 million, reflecting strong demand and a 40% reduction in risk of progression compared to earlier treatments. With its robust pipeline of therapeutics and a history of profitability, Genmab is well-positioned to navigate the challenging biotech sector while potentially delivering multiple near- and medium-term clinical data catalysts.

Bears say

Genmab's stock outlook is negatively impacted by several key risks, primarily the slowing sales of its leading product, Darzalex, along with the potential failure to secure label extensions for this therapy. The recent failure of Epcoritamab (Epkinly) in clinical trials to demonstrate a significant improvement in overall survival has led to decreased expectations for its approval timeline, which has been revised downward. Furthermore, there are concerns regarding the company's ability to penetrate markets with other therapies, the risk of dilution, and broader macroeconomic factors that could adversely affect financial performance.

GMAB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GMAB has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.